Mahmoud Alhariri: Apixaban in Hemodialysis-Treated Kidney Failure With Newly Diagnosed AF
Mahmoud Alhariri, Senior Attending Physician at Helios Universitätsklinikum Wuppertal, Hypertensiologe at Deutsche Hochdruckliga e.V. DHL, Lipidology Specialist at Deutsche Gesellschaft für Lipidologie e. V. (DGFL), shared a post on LinkedIn about a recent article by Wolfgang C. Winkelmayer et al., published in American Journal of Kidney Diseases, adding:
“Among patients with hemodialysis-treated kidney failure, compared with no anticoagulation, initiation of apixaban soon after newly diagnosed AF was associated with lower risks of ischemic stroke, a composite thromboembolic end point, and all-cause mortality but higher rates of clinically meaningful bleeding.”
Title: Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis
Authors: Wolfgang C. Winkelmayer, Kevin F. Erickson, Pascale Khairallah, Mingyue He, Maria E. Montez-Rath, Tara I. Chang, Jingbo Niu
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 14:32Kenneth Nollet: Building the Future of Transfusion Laboratory Science
-
Aug 21, 2026, 14:14Tareq Abadl: A Positive Antibody Screen is Not The Diagnosis
-
Aug 21, 2026, 14:08Katrina Snow։ Transfusion Trends and Quality Improvement in Sickle Cell Disease
-
Aug 21, 2026, 14:00Rucha Patil: The Power of Point-of-Care Testing in Hemostasis
-
Aug 21, 2026, 13:56Sarah Kowalski։ Supporting the Next Generation of Transfusion Laboratory Scientists
-
Aug 21, 2026, 13:51Join EHC 2026 Annual Conference
-
Aug 21, 2026, 12:57David McIntosh: Why Do Blood Supplies Still Fall Short?
-
Aug 21, 2026, 12:48Joshua Penrod: 35 Years of Progress in Plasma Safety
-
Aug 21, 2026, 12:42Moustafa Abdou: Diagnosis and Management of Pyruvate Kinase Deficiency